G20 Delegates Visit Bharat Biotech’s Genome Valley Plant and Call It a Shining Star

During the third health working group meeting of G20 India, delegates were given the opportunity to visit Bharat Biotech’s Genome Valley plant in Hyderabad. The delegation was impressed by the facility’s capabilities in vaccine production, observing how Bharat Biotech produced the country’s first anti-Covid vaccine: Covaxin. The delegates praised the plant for its impressive technology and inspiring story of investment and development. They also noted that the vaccine development work being carried out at the facility was both sophisticated and advanced. The visit was part of a larger trip to the Genome Valley, an organized cluster for life sciences research and development, which alone accounts for 33% of global vaccine production, including vaccines for COVID-19, polio, and rotavirus. The plant and the Genome Valley’s research and innovation institutions highlight India’s focus on health emergency prevention, preparedness, and response as well as strengthening cooperation in the pharmaceutical sector with a focus on safe, effective, quality, and affordable medical countermeasures. The delegation’s visit to the Genome Valley and the Bharat Biotech facility provided an opportunity to see India’s capabilities in vaccine production and research and development firsthand.